Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis

Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drug